Catalog No.: PC-25470Not For Human Use, Lab Use Only.
TRPA1 agonist NMTA is a selective, nonelectrophilic transient receptor potential ankyrin 1 (TRPA1) agonist with EC50 of 50.05 uM for hTRPA1, induces Ca2+ influx and exhibits antinociceptive effects.
TRPA1 agonist NMTA is a selective, nonelectrophilic transient receptor potential ankyrin 1 (TRPA1) agonist with EC50 of 50.05 uM for hTRPA1, induces Ca2+ influx and exhibits antinociceptive effects.
NMTA does not activate hTRPV1, mTRPV2, hTRPV3, hTRPV4, hTRPC6 and hTRPM8 channels individually expressed in HEK-293T cells.
NMTA (10-3000 μM) could activate mTRPA1 channels in a concentration-dependent manner (EC50=314.04 uM), activated and desensitized mTRPA1 channels.
NMTA (10, 20, and 40 mg/kg, oral) demonstrates antinociceptive effects on CFA-induced inflammatory pain in mice.
Physicochemical Properties
M.Wt
262.37
Formula
C14H18N2OS
Appearance
Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
N-(3-methoxypropyl)-4-(p-tolyl)thiazol-2-amine
References
1. Sun C, et al. ACS Chem Neurosci. 2025 Sep 3;16(17):3257-3266.
